Black checkmark with a sparkle and a curved line underneath on a white background.
Company

NextCure, Inc.

Ticker
NXTC
Sector
Industry
Report date
November 10, 2026
Valye AI Score

66

High visibility
Recent developments
Recent developments summary

Recent developments for NextCure include announcements and progress related to the proposed merger with Avere Therapeutics, Q2 financial results reflecting a loss amid strategic shifts, and clinical pipeline updates with planned data readouts in 2026.

Recent developments:
  • NextCure and Avere Therapeutics announced a merger agreement to advance oral IL-23 therapy, with the merger subject to customary closing conditions including stockholder approvals and NASDAQ listing requirements [N1][N4].
  • NextCure reported a widened Q2 loss as the proposed Avere merger reshapes the company’s strategic direction [N2].
  • NXTC stock experienced gains following the merger deal announcement, reflecting market interest in the combined entity’s potential [N3].
  • NextCure highlighted progress across its ADC pipeline and extended its cash runway into 2027, supporting ongoing clinical development [N8].
  • The company plans to provide clinical trial updates for its LNCB74 ADC candidate in the second half of 2026 [N2].
Overview

NextCure, Inc. operates as a clinical-stage biopharmaceutical company specializing in targeted therapies for oncology, primarily through antibody-drug conjugates (ADCs). The company’s pipeline focuses on two main ADC candidates: SIM0505, targeting cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor payload, and LNCB74, targeting B7-H4 with a tubulin inhibitor payload. Both candidates are in Phase 1 clinical trials, with SIM0505 being developed in collaboration with Simcere Zaiming Pharmaceutical Co., Ltd., and LNCB74 co-developed with LigaChem Biosciences. NextCure also pursues partnerships or financing for additional clinical and preclinical programs in oncology and non-oncology indications. The company is engaged in a proposed merger with Avere Therapeutics to advance oral IL-23 therapy. Financially, NextCure reported a net loss for Q3 2026 and maintains liquidity sufficient to cover current liabilities as of September 30, 2026.

Executive summary

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) targeting cancer patients with unmet needs. The company’s lead candidates include SIM0505, targeting CDH6, and LNCB74, targeting B7-H4, both in Phase 1 clinical trials with planned data updates in 2026. NextCure has strategic collaborations with Simcere Zaiming and LigaChem Biosciences for development and commercialization. The company reported a net loss of $6.846 million and had $8.728 million in cash as of September 30, 2026, with liquidity ratios indicating coverage of short-term liabilities. NextCure is pursuing a merger with Avere Therapeutics, which is subject to customary closing conditions and presents execution risks. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for NXTC

Bull case model:

NextCure’s advancement of two differentiated ADC candidates in Phase 1 trials, supported by strategic partnerships with Simcere Zaiming and LigaChem Biosciences, demonstrates a focused pipeline with potential clinical and regulatory milestones. The company’s approach to targeting validated oncology markers with proprietary payloads and optimized therapeutic windows may offer improved safety and efficacy profiles. The proposed merger with Avere Therapeutics could provide additional resources and broaden the therapeutic portfolio, enhancing strategic positioning in oncology.

Bear case model:

Risks include the uncertainty of clinical trial outcomes for early-stage ADC candidates, potential delays or failure to complete the proposed merger with Avere Therapeutics, and financial constraints evidenced by net losses and stockholders’ equity below NASDAQ listing requirements. The merger process has diverted management attention and incurred significant costs, which may impact ongoing operations. Failure to maintain NASDAQ listing or secure alternative financing could adversely affect liquidity and operational continuity. The contingent value rights associated with legacy assets carry uncertainty regarding potential payments to stockholders.

Moat:

NextCure’s competitive advantage lies in its focused expertise in antibody-drug conjugates targeting clinically validated oncology markers CDH6 and B7-H4, leveraging proprietary payload technologies and strategic collaborations that accelerate clinical development and regulatory timelines. The company’s dual payload approach addresses mechanisms of resistance and aims to maximize tumor eradication, particularly in gynecological cancers requiring sequential ADC therapies. Exclusive licensing agreements and co-development partnerships provide access to novel ADC candidates and platform technologies, supporting differentiation in a competitive oncology market.

Risks overview
Risks summary
The primary risks for NextCure include the uncertainty of completing the proposed merger with Avere Therapeutics, compliance with NASDAQ listing requirements, and the financial and operational challenges associated with early-stage clinical development and ongoing losses.
Risks details:

• Merger Completion Risk: The proposed merger with Avere Therapeutics is subject to customary closing conditions including stockholder and regulatory approvals. Failure to complete the merger on expected terms or timing could adversely affect NextCure’s business, financial condition, and operations [S2].
• NASDAQ Listing Compliance: NextCure’s stockholders’ equity was below the minimum required for continued listing on The Nasdaq Global Select Market as of September 30, 2026, posing a risk of delisting or transfer to another Nasdaq tier, which could impact liquidity and market perception [S2].
• Financial and Operational Risks: The company reported a net loss of $6.846 million for Q3 2026 and relies on financing activities and partnerships to fund operations. Costs related to the merger and ongoing clinical development may increase operating losses and strain resources [S2].
• Clinical Development Uncertainty: NextCure’s ADC candidates are in early clinical stages with inherent risks of trial delays, safety or efficacy issues, and regulatory challenges that could impact development timelines and commercial potential [S1].
• Contingent Value Rights Uncertainty: Payments under the contingent value rights agreement depend on successful disposition of legacy assets within specified timeframes, with no assurance of proceeds or payments to stockholders [S2].

FINAL FORECAST FOR NXTC

Final take one line
NextCure, Inc. is a clinical-stage biopharmaceutical company with a focused ADC oncology pipeline, engaged in a proposed merger with Avere Therapeutics, facing execution and financial risks amid ongoing clinical development.
Final take 12 to 24 month view

Business trends: Advancement of ADC candidates SIM0505 and LNCB74 in Phase 1 trials with strategic partnerships and merger activity shaping company direction.
Execution milestones: Phase 1 dose escalation data readouts planned in 2026; completion of merger with Avere Therapeutics; clinical trial updates and potential registrational trial preparations.
Key risks: Uncertainty of merger completion, NASDAQ listing compliance challenges, financial losses, clinical development risks, and contingent value rights payment uncertainties.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

66
LLM visibility overview
LLM Visibility known facts
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-05 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-08-12 | www.nasdaq.com | RTW Bio's Avere To Merge With NextCure | https://www.nasdaq.com/articles/rtw-bios-avere-merge-nextcure
  • N2 | 2026-08-10 | www.nasdaq.com | NextCure Reports Q2 Loss As Proposed Avere Merger Reshapes Strategic Direction | https://www.nasdaq.com/articles/nextcure-reports-q2-loss-proposed-avere-merger-reshapes-strategic-direction
  • N3 | 2026-07-15 | www.nasdaq.com | Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict | https://www.nasdaq.com/articles/top-biotech-gainers-nxtc-soars-merger-deal-bmgl-moves-past-nasdaq-woes-otlk-awaits-fda
  • N4 | 2026-07-14 | www.nasdaq.com | NextCure And Avere Therapeutics Announce Merger To Advance Oral IL-23 Therapy; Stock Up | https://www.nasdaq.com/articles/nextcure-and-avere-therapeutics-announce-merger-advance-oral-il-23-therapy-stock
  • N5 | 2026-07-08 | www.nasdaq.com | 3 Cancer Stocks to Watch as Oncology Innovation Accelerates | https://www.nasdaq.com/articles/3-cancer-stocks-watch-oncology-innovation-accelerates
  • N6 | 2026-05-11 | www.nasdaq.com | LUCID CAPITAL MARKETS Initiates Coverage of NextCure (NXTC) with Buy Recommendation | https://www.nasdaq.com/articles/lucid-capital-markets-initiates-coverage-nextcure-nxtc-buy-recommendation
  • N7 | 2026-03-05 | www.nasdaq.com | NextCure Advances with New Cancer Drug Application | https://www.nasdaq.com/articles/nextcure-advances-new-cancer-drug-application
  • N8 | 2026-01-23 | www.nasdaq.com | Next Cure Highlights Progress Across ADC Pipeline As Company Extends Cash Runway Into 2027 | https://www.nasdaq.com/articles/next-cure-highlights-progress-across-adc-pipeline-company-extends-cash-runway-2027
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine